First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors

BACKGROUND: Preclinically, interleukin-15 (IL-15) monotherapy promotes antitumor immune responses, which are enhanced when IL-15 is used in combination with immune checkpoint inhibitors (ICIs). This first-in-human study investigated NIZ985, a recombinant heterodimer comprising physiologically active...

Descripción completa

Detalles Bibliográficos
Autores principales: Leidner, Rom, Conlon, Kevin, McNeel, Douglas G, Wang-Gillam, Andrea, Gupta, Sumati, Wesolowski, Robert, Chaudhari, Monica, Hassounah, Nadia, Lee, Jong Bong, Ho Lee, Lang, O’Keeffe, Jessica A, Lewis, Nancy, Pavlakis, George N, Thompson, John A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619015/
https://www.ncbi.nlm.nih.gov/pubmed/37907221
http://dx.doi.org/10.1136/jitc-2023-007725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619015/
https://www.ncbi.nlm.nih.gov/pubmed/37907221
http://dx.doi.org/10.1136/jitc-2023-007725

Ejemplares similares